Press release
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to Reach USD 2.3 Billion by 2034
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often risky and incomplete. The approval of MEK inhibitors has transformed the treatment landscape, offering the first targeted therapies for NF1-PN. Combined with genetic testing, patient advocacy, and growing clinical research, the NF1-PN market is set for strong expansion over the next decade.
Market Overview
• Market Size (2024): USD 1.05 billion
• Forecast (2034): USD 2.3 billion
• CAGR (2025-2034): 8.1%
The NF1-PN market is entering a growth phase as MEK inhibitors such as selumetinib (Koselugo) gain adoption, supported by global rare disease programs and increased clinical trial activity.
Key Highlights:
• Selumetinib is the first FDA- and EMA-approved therapy for NF1-PN.
• Strong pipeline of MEK inhibitors and other targeted therapies.
• Expanding genetic diagnostics improving early detection.
• Patient advocacy groups driving awareness and trial recruitment.
Segmentation Analysis
By Product Type:
• Targeted Therapies
o MEK Inhibitors (Selumetinib, Mirdametinib, Trametinib - pipeline/repurposed)
• Surgical Interventions
o Tumor Resection (limited use due to complexity)
• Supportive Care
o Pain Management
o Physiotherapy & Rehabilitation
• Genetic Testing & Counseling Services
By Platform:
• Small Molecules
• Biologics
• Genetic Testing Platforms
By Technology:
• Molecular Targeted Therapy Platforms
• AI-Driven Imaging & Tumor Monitoring
• Next-Gen Genetic Sequencing
By End Use:
• Hospitals
• Specialty Oncology & Neurology Clinics
• Research Institutes
• Genetic Counseling Centers
By Application:
• Pediatric NF1-PN Patients
• Adult NF1-PN Patients
• Clinical Research
Segmentation Summary:
Targeted therapies, led by MEK inhibitors, dominate the current market. Genetic testing and AI imaging technologies are expanding patient identification and monitoring, while supportive care remains essential in comprehensive management.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71719/neurofibromatosis-type-1-associated-plexiform-neurofibromas-nf1-pn-market
Regional Analysis
North America
• Largest market with ~49% share in 2024.
• U.S. leads with FDA approval of selumetinib and strong insurance coverage for rare diseases.
• Well-developed patient registries and advocacy networks.
Europe
• Holds ~30% share.
• EMA approval of selumetinib driving adoption in Germany, UK, and France.
• Strong role of rare disease research initiatives and clinical trials.
Asia-Pacific
• Fastest-growing region with CAGR of ~9.4%.
• Japan, China, and India expanding genetic diagnostics and rare disease care.
• Growing clinical research participation and registry development.
Middle East & Africa
• Smaller market due to limited infrastructure.
• Gradual expansion of tertiary oncology centers.
Latin America
• Brazil and Mexico drive regional demand.
• Expanding access to MEK inhibitors and diagnostic tools.
Regional Summary:
North America and Europe dominate due to early therapy approvals and established rare disease frameworks, while Asia-Pacific represents the fastest growth opportunity with expanding awareness and healthcare access.
Market Dynamics
Key Growth Drivers:
• FDA/EMA approval of selumetinib creating a new treatment paradigm.
• Rising investment in MEK inhibitor pipelines.
• Expansion of genetic testing and counseling programs.
• Patient advocacy groups accelerating awareness and support.
Key Challenges:
• High cost of targeted therapies limiting access.
• Lifelong management required due to tumor recurrence risk.
• Limited availability of treatments in emerging economies.
• Small patient pool restricting large-scale commercial investment.
Latest Trends:
• Development of next-generation MEK inhibitors with improved tolerability.
• AI-assisted MRI for tumor growth monitoring.
• Research into combination regimens for NF1-PN management.
• Increasing collaboration between biotech firms and academic centers.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71719
Competitor Analysis
Major Players in the Market:
• AstraZeneca plc (Selumetinib/Koselugo)
• SpringWorks Therapeutics (Mirdametinib - pipeline)
• Novartis AG (Trametinib - repurposed research)
• Roche Holding AG
• Pfizer Inc.
• Bristol Myers Squibb (BMS)
• Eli Lilly and Company
• Amgen Inc.
• Illumina, Inc. (genetic diagnostics)
• Quest Diagnostics
Competitive Summary:
AstraZeneca leads the NF1-PN market with selumetinib, the first approved targeted therapy. SpringWorks is advancing mirdametinib in late-stage trials, while Novartis explores trametinib's potential. Diagnostics players like Illumina and Quest support patient identification. Competition is focused on next-gen MEK inhibitors, combination therapies, and global expansion.
Conclusion
The Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market, valued at USD 1.05 billion in 2024, is projected to reach USD 2.3 billion by 2034, growing at a CAGR of 8.1%. The market is being reshaped by targeted therapies, genetic diagnostics, and patient advocacy, offering new hope to patients worldwide.
Key Takeaways:
• Selumetinib has established a new treatment standard for NF1-PN.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Genetic testing and AI imaging are improving diagnosis and monitoring.
• Next-gen MEK inhibitors and combination regimens represent the future.
The next decade will see NF1-PN management evolve from surgical reliance to precision-targeted therapies and AI-driven monitoring, creating strong opportunities for pharmaceutical innovators, diagnostics firms, and healthcare providers.
This report is also available in the following languages : Japanese (神経線維腫症1型関連叢状神経線維腫(NF1-PN)市場), Korean (1형 신경섬유종증 관련 총상신경섬유종(NF1-PN) 시장), Chinese (1 型神经纤维瘤病相关丛状神经纤维瘤 (NF1-PN) 市场), French (Marché des neurofibromes plexiformes associés à la neurofibromatose de type 1 (NF1-PN)), German (Markt für plexiforme Neurofibrome (NF1-PN) im Zusammenhang mit Neurofibromatose Typ 1), and Italian (Mercato dei neurofibromi plessiformi associati alla neurofibromatosi di tipo 1 (NF1-PN)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71719/neurofibromatosis-type-1-associated-plexiform-neurofibromas-nf1-pn-market#request-a-sample
Our More Reports:
North America Non-Vascular Stents Market
https://exactitudeconsultancy.com/reports/72348/north-america-non-vascular-stents-market
EU5 Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72349/eu5-hernia-repair-devices-market
BRIC Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72350/bric-hernia-repair-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to Reach USD 2.3 Billion by 2034 here
News-ID: 4177698 • Views: …
More Releases from Exactitude Consultancy
Candidemia Market Growth, Trends, Consumer Demand and Key Opportunities
Introduction
Candidemia, a bloodstream infection caused by Candida species, is one of the most severe forms of invasive candidiasis. It represents a major healthcare challenge worldwide, particularly in immunocompromised individuals, intensive care unit (ICU) patients, and those with central venous catheters. The infection is associated with high morbidity, mortality, and healthcare costs, making it a critical focus of antifungal research and hospital infection control programs.
The market is shaped by rising prevalence…
Tuberous Sclerosis Complex (TSC) Market to Reach USD 4.6 Billion by 2034
Tuberous Sclerosis Complex (TSC) is a rare, genetic multisystem disorder caused by mutations in the TSC1 or TSC2 genes. It is characterized by the development of benign tumors (hamartomas) in organs such as the brain, kidneys, heart, lungs, and skin. Clinical symptoms include epilepsy, developmental delays, autism spectrum disorder, skin lesions, and renal angiomyolipomas, making TSC a highly complex condition requiring multidisciplinary care.
Download Full PDF Sample Copy of Market Report…
Retinitis Pigmentosa (RP) Market to Reach USD 1.65 Billion by 2034
Retinitis Pigmentosa (RP) is a group of rare, inherited retinal disorders that cause progressive degeneration of photoreceptor cells (rods and cones) in the retina, leading to night blindness, loss of peripheral vision, and eventually complete blindness in severe cases. RP affects approximately 1 in 4,000 people worldwide and can be inherited in autosomal dominant, autosomal recessive, or X-linked patterns.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71715
Although no universal…
Aspergillosis Market Set to Witness Significant Growth by 2025-2034
Introduction
Aspergillosis is a group of fungal infections caused by the Aspergillus species, a common mold found in the environment. While exposure is frequent, serious illness occurs mainly in immunocompromised individuals, including patients with cancer, organ transplants, chronic lung disease, or long-term corticosteroid use. Forms of aspergillosis include allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and invasive aspergillosis (IA) - the latter often being life-threatening.
The global burden of aspergillosis is…
More Releases for NF1
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks…
Strong Growth Ahead: Neurofibromatosis Type 1 Market Size To Grow At Arecord 9.6 …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Neurofibromatosis Type 1 Market Size Expected to Be by 2034?
In recent times, the growth of the neurofibromatosis type 1 (NF1) market size has been robust. The market is predicted to escalate from $8.06 billion in 2024 to $8.86 billion in 2025, exhibiting a compound annual growth rate…
Neurofibromatosis Type 1 Pipeline: Emerging Targeted Therapies and Gene-Based Ap …
The treatment landscape for Neurofibromatosis Type 1 (NF1), a rare genetic disorder characterized by nerve sheath tumors, skin changes, and other systemic complications, is undergoing a pivotal transformation. Historically limited to symptomatic and surgical management, recent advances are driving the development of disease-modifying therapies that target the underlying genetic and molecular mechanisms. With no curative treatments available, there is a growing focus on MEK inhibitors, RAS/MAPK pathway modulators, and gene…
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market?
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new…
